Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7LDG7
UPID:
GRP2_HUMAN
Alternative names:
Calcium and DAG-regulated guanine nucleotide exchange factor I; Cdc25-like protein; F25B3.3 kinase-like protein
Alternative UPACC:
Q7LDG7; A6NDC7; O00538; Q9UL65
Background:
RAS guanyl-releasing protein 2, also known as Calcium and DAG-regulated guanine nucleotide exchange factor I, plays a pivotal role in cellular signaling. It activates Rap and other GTPases, influencing platelet aggregation, T-lymphocyte and neutrophil adhesion, and possibly muscarinic acetylcholine receptor M1/CHRM1 signaling pathways.
Therapeutic significance:
Linked to Bleeding disorder, platelet-type, 18, this protein's dysfunction highlights its critical role in platelet function. Understanding the role of RAS guanyl-releasing protein 2 could open doors to potential therapeutic strategies for managing bleeding disorders.